Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Becton, Dickinson And Company (BDX) Stock Analysis: Exploring A 14% ...

AI-generated analysis

📈 Becton, Dickinson and Company (BDX) trades at $155.92 with a market cap of $42.96 billion in the healthcare sector.

🎯 Analysts project a 14% upside potential with an average target price of $177.75 based on current valuation metrics.

💰 The company reports robust free cash flow exceeding $4.5 billion, supporting operations and future ventures.

📊 BDX exhibits a forward P/E ratio of 11.64 and revenue growth rate of 5.20%, indicating strong financial performance.

💵 Investors receive a dividend yield of 2.69% with an EPS of $5.72 and a return on equity of 6.67%.

📉 Analyst sentiment is positive with six buy ratings, eight hold ratings, and no sell ratings currently active.

📈 Technical analysis shows the stock trading above its 50-day moving average with an RSI of 55.75 indicating neutral momentum.

🤝 BDX's strategic collaboration with ChemoGLO highlights a commitment to enhancing safety measures in healthcare settings.

🔮 The target price range spans from $150.00 to $225.00, offering various market scenarios for investors.

Bullish Signals
  • BDX exhibits a potential upside of 14% with an average analyst target price of $177.75, suggesting growth-focused investors may find value.
  • The company's forward P/E ratio of 11.64 indicates it is relatively undervalued compared to industry peers.
  • BDX demonstrates a solid revenue growth rate of 5.20%, underscoring its capability to sustain financial performance in the competitive medical supplies industry.
  • Robust free cash flow of over $4.5 billion reflects strong cash generation capacity, critical for sustaining operations and funding new ventures.
  • Analyst sentiment is largely positive with six buy ratings and eight hold ratings, indicating confidence in long-term growth prospects.
  • The stock is trading above its 50-day moving average of $148.23, suggesting a bullish trend may be forming.
  • Strategic collaboration with ChemoGLO underscores the company's commitment to innovation and enhancing safety measures within healthcare settings.
Full Analysis
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical instruments and supplies with a market capitalization of $42.96 billion. Headquartered in Franklin Lakes, New Jersey, the company serves healthcare institutions, life science researchers, and the pharmaceutical industry. Currently trading at $155.92, the stock has shown stability with a recent price change of 0.03% within a 52-week range spanning from $135.42 to $185.39. Analysts project a potential upside of 14% for BDX, supported by an average target price of $177.75 and a forward P/E ratio of 11.64, which suggests the stock is relatively undervalued compared to peers. The company demonstrates strong financial health with revenue growth of 5.20%, robust free cash flow exceeding $4.5 billion, and an earnings per share (EPS) of 5.72. Additionally, BDX offers a dividend yield of 2.69% with a payout ratio of 72.95%, providing reliable income for investors. Technical indicators indicate that BDX is trading above its 50-day moving average and near its 200-day moving average, with an RSI of 55.75 suggesting the stock is neither overbought nor oversold. Analyst sentiment remains positive with six buy ratings and eight hold ratings, while no sell ratings are present. The strategic collaboration with ChemoGLO further underscores the company's commitment to innovation and safety within healthcare settings. With a target price range between $150.00 and $225.00, BDX presents an opportunity for investors seeking long-term growth and stability in the healthcare sector. The combination of solid valuation metrics, strong cash generation, and strategic partnerships positions the company well for future expansion. Investors considering a diversified portfolio may find BDX's stock attractive given its efficient utilization of shareholder equity and positive analyst outlook.